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 Abstract 
 
Objective: Pancreaticoduodenectomy is the standard of care for tumours confined to the head of 
pancreas and can be undertaken with low operative mortality. The procedure has a high morbidity, 
particularly in older patient populations with pre-existing co-morbidities. This study evaluates the role of 
cardiopulmonary exercise testing (CPET) as a means of predicting post-operative morbidity and 
outcome in high-risk patients undergoing pancreaticoduodenectomy. 
Methods: In a prospective cohort of consecutive patients undergoing pancreaticoduodenectomy, those 
aged over 65 years (or younger with co-morbidity) were categorized as high-risk and underwent 
preoperative assessment by CPET according to a pre-defined protocol. Data were collected on 
functional status, postoperative complications and survival.  
Results:  143 patients underwent preoperative assessment of whom 50 were deemed low-risk for 
surgery per protocol. Of 93 high-risk patients 64 proceeded to surgery after preoperative CPET. Neither 
Anaerobic threshold (AT) nor maximal oxygen consumption (V O2 MAX) predicted patient mortality or 
morbidity. However ventilatory equivalent of carbon dioxide (V E/V CO2) at AT was a predictive marker 
of postoperative mortality with an AUC of 0.84 (95% CI 0.63 to 1.00, p=0.020); a threshold of 41 was 
75% sensitive and 95% specific (PPV 50%, NPV 98%). Above this threshold, raised V E/V CO2 
predicted poor long-term survival (HR 2.05, 95% CI: 1.09 to 3.86, p=0.026).   
Conclusions: CPET is a useful adjunctive test for predicting post-operative outcome in patients being 
assessed for pancreaticoduodenectomy.  Raised CPET-derivedV E/V CO2 predicts early post-operative 
death and poor long-term survival. 
[Word count 238]. 
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Introduction  
Surgical resection is the standard of care for patients with tumours confined to the head of the pancreas 
[1-3]. An increasing number of reports attest that pancreaticoduodenectomy can be performed with low 
operative mortality [2, 4].  However, perioperative morbidity remains high and the risk-benefit ratio of 
complex resectional surgery must be carefully assessed [5]. Thus one of the principal thrusts of current 
pancreatic oncological surgery is towards optimal patient selection.   
Detailed oncological staging can be undertaken with a combination of high-resolution cross-sectional 
imaging combined with endoscopic ultrasonography.  Assessment of risk in terms of cardio-respiratory 
co-morbidity is an integral component of pre-operative assessment.  This is particularly relevant when it 
is considered that pancreatic adenocarcinoma is predominantly a disease of later life and that patients 
assessed for resection may be at high risk for post-operative cardiac or pulmonary complications. 
Furthermore, postoperative complications may affect uptake of adjuvant chemotherapy potentially 
leading to adverse outcome [6]. 
Current methods of evaluating perioperative risk rely on tools comprising subjectively derived 
assessments of functional capacity, such as the Revised Cardiac Risk Index (RCRI) or the Physiological 
and Operative Severity Score for Enumeration of Morbidity and Mortality (POSSUM). These measures 
along with other forms of functional assessments (shuttle walk test, Duke’s score) have been shown to 
be poor surrogates for functional cardiopulmonary assessment [7.8]. 
Cardiopulmonary exercise testing (CPET) provides an accurate and reliable non-invasive assessment of 
cardiopulmonary function.  CPET-derived variables have been demonstrated to provide prognostic 
information relating to outcome following major intra-abdominal surgery [7, 9]. Despite validation in a 
heterogeneous general surgical population, its evaluation in pancreatic resectional surgery is very 
limited either in an exclusive cohort or as an independently-reported subgroup of a broader cohort.  
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Thus the aim of the present study is to assess the role of preoperative CPET for prediction of peri-
operative outcome in a cohort of patients scheduled to undergo pancreaticoduodenectomy. 
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Methods  
Study design  
This was a single-centre prospective cohort study evaluating outcome in patients undergoing 
pancreaticoduodenectomy.  Cardiopulmonary exercise testing (CPET) was utilised for preoperative risk 
assessment in protocol-defined high risk patients.  
Study population 
The study cohort comprised a consecutive series of patients undergoing pancreaticoduodenectomy at a 
tertiary hepatobiliary surgery referral centre. The study was undertaken over a 39-month period from 1st 
September 2007 to 31st December 2010. Staging of primary disease was undertaken using high-
resolution, contrast-enhanced computed tomography together with endoscopic ultrasound (EUS) (and 
EUS-guided fine needle aspiration for cytological and biochemical analysis) in patients with cystic 
lesions.  Patients presenting with obstructive jaundice routinely underwent endoscopic retrograde 
cholangiopancreatography (ERCP) with placement of an endobiliary stent or percutaneous trans-hepatic 
biliary drainage (PTBD).  
Following clinical assessment, those individuals with pre-existing co-morbidity (definitions in disease 
descriptors section) or aged over 65 years were further assessed by preoperative CPET in compliance 
with a pre-defined hepato-pancreato-biliary unit protocol. These patients were classified as ‘high-risk’. 
Younger individuals (≤65 years) with no significant pre-existing co-morbidity proceeded to surgery 
without preoperative CPET and were classified as the ‘low-risk’ group. 
Patient-level data and disease descriptors 
Baseline data were recorded for all patients including age, gender and preoperative haematological and 
biochemical profile which included full blood count, liver function tests, renal function tests and C 
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reactive protein. Operative details (duration of surgery and intra-operative blood transfusion) were also 
recorded.  
The primary outcome studied was postoperative mortality (defined as death within 30 days of 
operation). Secondary outcomes included in-hospital mortality occurring beyond the 30th postoperative 
day (time unlimited), intensive care unit (ICU – level III critical care) stay, high dependency unit (HDU – 
level II critical care) stay, overall hospital stay and longer-term survival with follow-up to four years. 
Long-term survival was also evaluated separately in patients who underwent preoperative assessment 
with CPET, but failed to undergo pancreatic resection either because of advanced disease or because 
they were deemed unfit for major surgery. 
An enhanced set of data were obtained for patients undergoing CPET including self-reported history of 
smoking and preoperative co-morbidities. Preoperative co-morbidity was recorded at initial clinical 
assessment and included data on the following: cardiac – history of hypertension or ischaemic heart 
disease; diabetes mellitus (insulin dependent or otherwise); history of cerebrovascular disease; and, 
chronic obstructive airways disease or renal impairment (defined according to the National Institute for 
Health and Clinical Excellence guidance on chronic kidney disease) [10].  In this subset, preoperative 
functional status was assessed using the American Society of Anaesthesiologists (ASA) score and the 
six-point Revised Cardiac Risk Index (RCRI); including high-risk surgical procedure, history of ischaemic 
heart disease, history of heart failure, cerebrovascular disease, insulin dependent diabetes and 
preoperative serum creatinine concentration ≥177 μmol/L. Other predictors of postoperative risk 
including body mass index (BMI) and the Glasgow Prognostic Score (GPS) [11] were collected 
prospectively to permit comparison with CPET data. 
Postoperative morbidity was defined using the International Study Group [11] for Pancreatic Surgery 
(ISGPS) classification for post-pancreaticoduodenectomy complications of postoperative pancreatic 
fistula (POPF) [12] delayed gastric emptying (DGE) [13] and post-pancreaticoduodenectomy 
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haemorrhage (PPH) [14]. Cardiac complications included acute myocardial infarction (detection of a rise 
in serum troponin) and electrocardiographic (ECG) changes indicative of new ischaemia; congestive 
cardiac failure and, serious dysrhythmia resulting in compromised tissue perfusion and primary cardiac 
arrest. Pulmonary complications included pneumonia, pleural effusion and respiratory failure requiring 
ventilatory support. Renal complications included acute kidney injury defined as an increase in baseline 
creatinine of 1.5 fold and/or requirement for renal replacement therapy. Other recorded complications 
included confusion, cerebrovascular accidents, wound infections, thromboembolic events, intra-
abdominal sepsis and interventions (radiological, endoscopic or surgical) which included return to 
theatre. Complications were recorded for the entire postoperative in-hospital period. 
Data were recorded prospectively and analysed at completion of the study. All-cause mortality was 
determined using the Demographics Batch Service (DBS) to access the national electronic database of 
the UK NHS (National Health Service).  
Cardiopulmonary exercise testing protocol 
Preoperative cardiopulmonary exercise testing was carried out once the decision to undertake 
pancreaticoduodenectomy was made and patients met the inclusion criteria for CPET as per protocol. 
CPET results were available to clinicians prior to surgery. An established study protocol [15] was 
followed and the test was carried out and interpreted by two observers (a clinical scientist and an 
attending anaesthetist).  CPET equipment (UltimaTM CardiO2®, MedGraphics, Minnesota, USA) included 
an electronically braked cycle ergometer with a 12 lead ECG and a metabolic cart with a face mask for 
gas analyses. Calibration was carried out before each test for flow measurement and gas analysers.  
The test was divided into four phases. The first phase involved a two to five minute rest period to ensure 
a respiratory exchange rate (RER) of less than 1. RER is the ratio of volume of carbon dioxide 
elimination (V CO2 L/min) to oxygen consumption (V O2 L/min).  The second phase of unloaded cycling 
for three minutes was followed by the ramp phase in continuous increments maintaining greater than 60 
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revolutions per minute (RPM). The test ended with the recovery phase to allow the ECG and heart rate 
to return to baseline levels. The test was terminated if patients developed ECG changes (ST changes > 
2.0 mm depression or > 3.0mm elevation, new dysrhythmia), near syncope or failed to maintain greater 
than 50 RPM.  
Anaerobic threshold (AT) was determined using the modified V-slope method [16, 17] and confirmed by 
changes in ventilatory efficiency for oxygen (V E /V O2) and end tidal values for oxygen (PETO2) in which 
V E (L/min) is minute ventilation representing volume of gas expired per minute. Peak V O2 was 
expressed as the highest mean oxygen consumption value (V O2) obtained from 5 rolling breath to 
breath measures during the last part of the incremental ramp stage. The ventilatory equivalence for 
carbon dioxide (V E/V CO2) was determined as the ratio of minute ventilation to carbon dioxide 
elimination (V CO2) at AT.  
Statistical methods 
Per protocol analysis was performed using SPSS (16.0, full-version Chicago, IL.), with appropriate 
statistical tests for each variable type. As the purpose of the study was hypothesis generation, a value 
of p <0.05 was regarded as significant, without correction for multiple testing. CPET (continuous) 
variables were evaluated using simple logistic regression to determine their potential prognostic value in 
predicting mortality or morbidity outcomes.  Logistic regression models include a constant term and are 
reported as the exponential of the variable coefficient (the odds ratio). If more than one variable 
predicting an outcome then forward stepwise multiple variable regression was conducted.  Significant 
CPET variables were further explored by plotting Receiver operating characteristic (ROC) curves to 
identify threshold values which discriminated effectively between patient groups with differing clinical 
outcomes.  
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Using these threshold values, survival analysis was conducted using the Kaplan Meier method to 
identify discrete groups with varying prognosis. Differences in survival curves were assessed using the 
log rank method as this gives equal weight to events at all points in time. Putative models were further 
evaluated using Cox regression.  
The study was registered as a prospective audit with the Research and Innovation Division of the 
Central Manchester University Hospitals NHS Foundation Trust (reference number 1840).  
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Results 
 
Over a 39-month period, from 1st September 2007 to 31st December 2010, 143 consecutive patients 
with operable pancreatic disease requiring pancreaticoduodenectomy were assessed for perioperative 
risk [Figure 1]. Per protocol, 93 patients were designated as ‘high-risk’ for preoperative assessment with 
CPET.  Of these, 4 were unable to undergo CPET prior to surgery and proceeded to resection (in view 
of surgeon and patient preference) without CPET; 64 underwent pancreaticoduodenectomy following 
CPET and a further 25 did not proceed to resection - because of a combination of staging-detected 
advanced disease and/or co-morbidity.  The ‘low-risk’ patient group comprised 50 patients all of whom 
underwent resection giving a total population of 118 undergoing pancreaticoduodenectomy.  
Baseline characteristics and postoperative outcomes in these 118 patients are described in Table 1. No 
significant difference was noted between the low and high-risk groups in the incidence of preoperative 
obstructive jaundice, use of preoperative biliary drainage, preoperative bilirubin levels or postoperative 
ICU stay. The duration of HDU and hospital stay was significantly longer in the high-risk group.  
An enhanced set of data collected in the high-risk CPET group is detailed in Table 2.  Of the 64 
consecutive pancreaticoduodenectomies, CPET was inadequate in 4 individuals leaving 60 patients 
contributing data to analyses.  
Postoperative mortality  
Early (30-day) and late (all in-hospital) postoperative deaths are reported in Table 1. Postoperative 
mortality was generally low with no significant difference between low and high-risk groups at 30 days 
(p=0.223).  All post-operative deaths resulted from surgical complications.  
In high-risk patients, simple logistic regression analyses identified V E/V CO2 to be the CPET parameter 
most strongly associated with 30-day mortality (OR: 1.35, 95%CI: 1.03 to 1.77, p=0.030). Simple 
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regression did not reveal any other CPET markers associated with early postoperative death (see Table 
3).  For in-hospital mortality, simple logistic regression similarly fitted V E/V CO2 (1.26 (95% CI: 1.06 to 
1.53, p=0.013).  
The Receiver Operating Characteristic (ROC) curves of V E/V CO2 for 30-day and all in-hospital 
postoperative mortality are shown in Figure 2. For 30-day mortality, the AUC was 0.95 (95% CI: 0.89 to 
1.02, p=0.030) with 100% sensitivity and 92% specificity. For all in-hospital mortality, the AUC was 0.84 
(95% CI: 0.63 to 1.07, p=0.020). Given the small number of deaths at 30-days, in hospital mortality was 
considered a more informative variable. A cut-off at 41.0 provided test sensitivity of 75% (95% CI: 0.30 
to 0.95), specificity of 93% (95% CI: 0.85 to 0.98), PPV of 50% (95% CI: 0.19 to 0.81) and NPV of 98% 
(95% CI: 0.90 to 0.99).  Thus a negative result effectively ruled out 30-day hospital mortality, while one 
in two patients above threshold died before discharge. 
Amongst traditional pre-operative markers (ASA, RCRI, BMI, GPS and obstructive jaundice), none were 
statistically significant predictors of 30-day or in-hospital mortality.  However, all 5 in-hospital deaths 
occurred in patients with ASA=3 (p=0.087 exact test).   
Postoperative morbidity  
No CPET preoperative variable was a significant predictor (p<0.05) of complications using simple 
logistic regression (Table 3). However obstructive jaundice was associated with cardiopulmonary 
complications (OR: 5.40, 95%CI: 1.66 to 17.56, p=.005) 
ISGPS defined post-pancreatectomy complications 
ISGPS defined complications of postoperative pancreatic fistula (POPF), post-pancreatectomy 
haemorrhage (PPH) and delayed gastric emptying (DGE) are reported in Table 2. Neither CPET nor 
other preoperative variables predicted ISGPS defined complications. 
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Survival  
The median period of follow-up for all 143 patients undergoing assessment for resection was 1057 days 
(424 to 1657). For the 118 patients undergoing pancreaticoduodenectomy the median follow-up period 
was 997 days (424 to 1596).  
Survival analysis (Kaplan Meier) identified discrete survival patterns using the CPET threshold value for 
V E/V CO2 of 41 [Figure 3].  Patients above this threshold had a substantially poorer survival than 
patients below this threshold (HR 2.05, 95% CI: 1.09 to 3.86, p=0.026).  For comparison the lower risk 
patient groups (not-undergoing CPET) are shown, with better survival due to lower age and associated 
risk markers. 
Histologic sub-types [ductal adenocarcinoma 27 (41%), ampullary 13 (20%), intraductal papillary 
mucinous neoplasm 5 (7%), distal duct cholangiocarcinoma 3 (5%), duodenal adenocarcinoma 3 (5%), 
chronic pancreatitis 3 (5%) neuro-endocrine tumour 2 (3%), metastatic seminoma 1 (2%), metastatic 
renal cancer 1 (2%), autoimmune pancreatitis 2 (3%), benign adenoma 3 (5%) and benign distal bile 
duct stricture 1 (2%)] showed no correlation with outcome (Log-Rank Mantel Cox test P = 0.72).  
However, ductal adenocarcinoma was associated with a worse survival when compared to all other 
tumour types (Log-Rank Mantel Cox Test P = 0.001). 
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Discussion   
This study reports an exploratory prospective cohort of high-risk patients undergoing 
pancreaticoduodenectomy with CPET for preoperative risk assessment. CPET-derived V E/V CO2 ratio 
at AT with a cut-off at 41 was the best predictor of postoperative in-hospital mortality and long-term 
survival in this high-risk pancreaticoduodenectomy population. Commonly used risk markers including 
ASA, RCRI, and BMI were not predictive of adverse outcome in this cohort, although this may be due to 
small numbers of events. 
There are a number of potential limitations when interpreting these findings. As in any hypothesis 
generating study, the findings should undergo external validation by other investigators in similar patient 
cohorts. The V E/V CO2 threshold was determined for a high-risk cohort of pancreaticoduodenectomy 
patients and was limited by a low event rate in postoperative mortality: further evaluation in a larger 
cohort would be required to validate the utility of this marker of postoperative mortality. Another potential 
limitation is the lack of blinding of CPET results to clinicians: the availability of results to inform decision 
making potentially undermines the strength of association between variables and outcome measures, 
although it is unlikely that CPET findings modified surgical decisions since their importance was not 
known at the time that patients underwent surgery.  
An important bias in accurate preoperative evaluation of cardiopulmonary function is introduced by the 
presence of malignant obstructive jaundice. Obstructive jaundice is known to adversely affect global 
cardiac function [18]. As increase in cardiac output remains the predominant mechanism of meeting 
increased oxygen demands following major abdominal surgery [19], the clinical impact of obstructive 
jaundice on postoperative outcomes in the context of pancreatic surgery remains unclear [20, 21].  
Further the subjective dichotomisation of patients into “high” and “low” risk means that CPET was not 
utilised in a group designated as low risk.  The reason for this is that CPET data from other studies 
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indicates that the validity of this test is maximal in assessing high-risk patients [22] but it should be 
acknowledged that if the test had been applied to all patients different results may have been obtained. 
In complex pancreatic resectional surgery, intra-operative factors including host-specific features (such 
as texture of pancreas, calibre of pancreatic duct), histology-related features (such as whether resection 
is for pancreatic ductal adenocarcinoma or other disease) and operator specific features (such as 
surgeon and hospital volume) have an important and profound influence on outcome.  Pre-operative 
CPET will not substitute for these important predictors but rather helps inform the decision on patient 
selection. 
Despite these shortcomings, a CPET-derived variable provided an adequate predictor of mortality-
related outcomes to augment the decision-making process, by predicting early and long-term survival.  
A V E/V CO2, threshold of 41 as a predictor of postoperative and long-term survival is similar to the 
findings of Carlisle and colleagues, reporting V E/V CO2 above 42 as the strongest predictor of 30 day 
and mid-term survival following elective abdominal aortic aneurysm repair [22].  
Our findings suggest that functional capacity as assessed by V E/V CO2 is a strong predictor of early 
and late postoperative outcome and may have a greater role to play than primary pancreatic pathology 
or resectability of cancer alone.   
Although it is clear that CPET-derived functional assessment outperforms other methods as a predictor 
of post-operative and long-term survival, its clinical utility in pancreaticoduodenectomy lies in acting as 
an adjunct to other forms of assessment and in allowing clinician and patient to make a more informed 
decision about the relative risks and benefits of surgery.  
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Table 1: Outcome from 118 pancreatic resections 
 
 
All patients High risk group* Low risk group p-value 
N  118 68 50 -  
Age in years  61 (36 – 80) 68 (45 – 80) 53 (36 – 65) <0.001 
Sex (male/female)  67/51 41/27 26/24 0.37 
Obstructive jaundice 71 (60%) 44 (65%) 27 (54%) 0.24 
Preoperative biliary drainage 70/71 (99%) 44/44 (100%) 26/27 (96%) 0.17 
Preoperative Bilirubin (µmol/L) 10 (2 – 323) 10.5 (2 – 216) 9.5 (2 – 323) 0.87 
ICU stay in days# 0 (0 – 194) 0 (0 – 194) 0 (0 – 24) 0.10 
HDU stay in days  5 (0 – 32) 5 (0 – 32) 4 (1 – 19) 0.003 
Hospital stay in days 16 (3 – 194) 18 (3 – 194) 13.5 (9 – 53) 0.005 
<30 day postoperative mortality  2 (1.7%) 2 (2.9%) 0 (0%) 0.22 
In-hospital postoperative mortality 5 (4.2%) 5 (7.4%) 0 (0%) 0.051 
Data presented as median (range) or count (%) unless otherwise indicated. The Mann-Whitney U test 
was used for continuous- and exact test for categorical variables. ICU, Intensive care Unit; HDU, High 
dependency Unit. *Includes 64 patients undergoing resection with preoperative CPET and 4 patients 
qualifying for CPET but not undertaken. 25 patients assessed as unfit for surgery following CPET are 
not included in this table (median age 69, range 60-84, sex M/F 15/10).  # With few ITU admissions 
postoperatively [14/118 patients (11.7% patients)], the median value was zero.  
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Table 2: Preoperative characteristics and postoperative outcomes for 64 patients who had 
resection after cardiopulmonary exercise testing 
 
 
 No. of patients* 
Age (years)† 64 (45-80) 
Sex ratio (M : F) 38:26 
Time between CPET and operation (days)† 13 (1–209) 
Body mass index (kg/m2)† 26 (15–44) 
ASA score† 3 (1–3) 
Revised Cardiac Risk Index† 1 (1–3) 
Glasgow Prognostic Score 0 (1-2) 
Obstructive Jaundice 43 (67%) 
Surgical procedure  
Whipple 57 (89%) 
Subtotal pancreatectomy (“Extended” Whipple) 2 (3%) 
Whipple +  liver + Gall bladder resection 1 (2%) 
Whipple + Portal vein resection 1 (2%) 
Total pancreatectomy 3 (5%) 
Postoperative outcomes  
Cardiac complications 15 (23%) 
Pulmonary complications 24 (38%) 
Cardiopulmonary complications 32 (50%) 
All complications 41 (64%) 
Return to theatre 3 (5) 
DGE (ISGPS grade, A=4, B=11, C=5) 20 (31.2%) 
PF (ISGPS grade, A=3, B=12, C=1) 16 (25%) 
PPH (ISGPS grade, A=0, B=5, C=0) 5 (7.8%) 
ICU stay (days) † 0 (0–194) 
HDU stay (days)† 5 (0–23) 
Hospital stay (days)† 18 (3–194)  
*With percentages in parentheses unless indicated otherwise; †values are median (range). CPET, 
cardiopulmonary exercise testing; ASA, American Society of Anaesthesiologists; COPD, chronic 
obstructive pulmonary disease; ISGPS, International Study Group for Pancreatic Surgery; DGE, Delayed 
Gastric Emptying; PF, post-pancreatectomy fistula; PPH, Post-pancreatectomy haemorrhage; ICU, 
intensive care unit; HDU, high-dependency unit. 
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Table 3: Evaluation of CPET variables and post-operative mortality and morbidity 
 
 Odds Ratio 95%CI p 
In Hospital Mortality    
AT 0.90 (0.52 to 1.53) 0.69 
V E/V CO2 1.26 (1.05 to 1.52) 0.013 
V O2 MAX 1.03 (0.77 to 1.37) 0.86 
30-day Mortality    
AT 1.23 (0.72 to 2.11) 0.45 
V E/V CO2 1.35 (1.03 to 1.77) 0.030 
V O2 MAX 1.32 (0.91 to 1.93) 0.14 
Cardiopulmonary Complication    
AT 1.05 (0.82 to 1.34) 0.68 
V E/V CO2 0.98 (0.90 to 1.07) 0.63 
V O2 MAX 1.00 (0.86 to 1.17) 0.98 
Any Complication    
AT 1.07 (0.83 to 1.39) 0.60 
V E/V CO2 0.97 (0.89 to 1.07) 0.56 
V O2 MAX 1.00 (0.86 to 1.18) 0.96 
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Figure 1: Flowchart 
 
 
 
 
 
 
 
Figure 1: Flow diagram showing patient inclusion. Patients aged 65 years or less without co-morbidity 
were classified as low risk. The high-risk group comprised patients older than 65 years or younger 
patients with co-morbidity. Four patients in the high-risk group who deviated from the protocol by 
undergoing pancreaticoduodenectomy without cardiopulmonary exercise training (CPET) were excluded 
from the analysis. Following risk assessment with CPET, 25 patients were unfit for surgery, either due to 
advanced disease (12) or on basis of perioperative risk (13). 
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Figure 2: ROC curves for V E/V CO2 as a predictor of postoperative (30-day)  
and in-hospital mortality 
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Figure 2: Receiver operating characteristic (ROC) curves for ventilatory equivalence of carbon dioxide 
(V E/V CO2), demonstrating the optimal cut-off for 30-day and all in-hospital mortality in patients who 
underwent resection after cardiopulmonary exercise testing. For 30-day mortality the area under the 
curve (AUC) was 0.95; sensitivity and specificity were 100 and 92 per cent respectively at a cut-off 
threshold of 41. For in-hospital death the AUC was 0.84; sensitivity and specificity were 75 and 93 per 
cent respectively at a cut-off threshold of 41. 
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Figure 3: Survival (Kaplan Meier) of the study cohort 
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 Number at risk 
Year 0 1 2 3 
Low risk 50 41 27 16 
High-risk V E/V CO2 <41 69 47 23 10 
High-risk V E/V CO2 ≥41 15 7 4 2 
 
 
 
 
 
 
Figure 3: Kaplan Meier survival characteristics of all patients groups: the curves displayed are truncated 
when less than 10% of the cohort remains. The low-risk resection group represented individuals 
younger than 65 years of age, with no co-morbidity (50). High-risk group included individuals with pre-
existing co-morbidity or age 65 years and over. 89 of these high-risk patients underwent preoperative 
CPET evaluation with 64 proceeding to resection. The remaining 25 patients were deemed inoperable 
either due to high operative risk (13) or advanced disease (12). CPET was inadequate in 4 patients 
undergoing resection and one patient with advanced disease. 84 patients providing data for survival 
analyses. 
Group Log rank test 
(1) Low risk (1) vs. (2), p=0.033 
(2) High-risk V E/V CO2 <41 (2) vs. (3), p=0.022 
(3) High-risk V E/V CO2 ≥41 (3) vs. (1), p<0.001 
